Result for
Topic: Vaccines and Immunity
May 13, 2021
Covid-19 Vaccine Acceptance in California State Prisons
67% of California prison residents offered a COVID-19 vaccine (n=64,633) accepted at least one dose through March 2021. Acceptance was highest among Hispanic (73%) and white residents (72%), and lowest among Black residents (55%). Acceptance was highest among residents aged ≥65 years and those at high risk for severe COVID-19 (>80%) and lowest among those…
May 12, 2021
Passive and Active Immunity in Infants Born to Mothers with SARS-CoV-2 Infection during Pregnancy: Prospective Cohort Study
[Pre-print, not peer-reviewed] In a cohort of US mothers testing positive for SARS-CoV-2 during pregnancy (n=145), anti-SARS-CoV-2 antibodies were detected in 65% and 58% of maternal and cord blood samples at delivery, respectively. The IgG transplacental transfer ratio was significantly higher among women receiving their first maternal positive PCR test 60-180 days before delivery compared…
Antibody Responses After a Single Dose of ChAdOx1 NCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-CoV-2
[Pre-print, not peer-reviewed] Sera of participants with detectable spike antibodies produced by natural infection had higher levels of anti-SARS-CoV-2 spike IgG antibodies against the wild-type strain and variants of concern (B.1.1.7, B.1351, and P.1) at least one week after a single dose of the Oxford-Astrazeneca vaccine (n=83) compared to sera from a mixed group of…
Cross-Sectional Serosurvey of Companion Animals Housed with SARS-CoV-2-Infected Owners, Italy
Anti-SARS-CoV-2 nucleocapsid (N) antibodies were detected in 7% of pets (14 of 198) in a serosurvey conducted in Italy from March to June 2020. All 14 seropositive animals lived with SARS-CoV-2-infected owners. In the households of SARS-CoV-2–infected owners, 20% (11 of 54) of cats and 3% (3 of 93) of dogs were seropositive. The proportion…
May 11, 2021
Demographic and Social Factors Associated with COVID-19 Vaccination Initiation Among Adults Aged =65 Years — United States, December 14, 2020–April 10, 2021
79% of US older adults (aged ≥65 years, n>42 million) have received at least 1 dose of a COVID-19 vaccine as of April 10, 2021. On average, counties with low vaccination rates (<50% of older adults) compared with counties with high vaccination rates (≥75% of older adults) had higher percentages of older adults who do…
Cerebral Venous Thrombosis and Portal Vein Thrombosis a Retrospective Cohort Study of 537913 COVID-19 Cases
[Pre-print, not peer-reviewed] Risk of diagnosis for cerebral venous thrombosis (CVT) and portal vein thrombosis (PVT) within 2 weeks of a COVID-19 diagnosis was 6.6-fold higher and 7.4-fold higher, respectively, compared to receiving a COVID-19 mRNA vaccine according to a retrospective study of administrative data in the US. Researchers compared patients with a COVID-19 diagnosis…
May 10, 2021
Vaccination Boosts Naturally Enhanced Neutralizing Breadth to SARS-CoV-2 One Year after Infection
[Pre-print, not peer-reviewed] Among 63 COVID-19 convalescent individuals assessed at 1.3, 6.2 and 12 months after infection, antibody reactivity to the receptor binding domain (RBD), neutralizing activity, and the number of RBD-specific memory B cells remained relatively stable from 6 to 12 months in those who had not been vaccinated. Among the 41% of the…
Short-Term Effects of BNT162b2 MRNA COVID-19 Vaccination on Physiological Measures a Prospective Study
[Pre-print, not peer-reviewed] A prospective study of adults (n = 160) in Israel who had not been previously infected with SARS-CoV-2 evaluated physiological changes in participants before and after their second Pfizer-BioNTech dose. Participants were given a chest-patch sensor to wear for four days, starting one day before vaccination. The sensor measured 13 physiological parameters…
Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine
[Pre-print, not peer-reviewed] Pooled estimates of vaccine-induced immune thrombotic thrombocytopenia (VITT) cumulative incidence among individuals who received Oxford-AstraZeneca/Covishield vaccine in 10 countries found an overall risk of 1 in 139,000. For those aged 65 and over, the risk was about 1 in 1,000,000, while for those under 55, the risk was between 1 in 20,000…
Progressive and Parallel Decline of Humoral and T Cell Immunity in Convalescent Health Care Workers with Asymptomatic or Mild-Moderate SARS-CoV-2 Infection
Among healthcare workers in Spain who recovered from COVID-19 (n = 22), T-cell response was significantly lower among those with early loss of antibodies (6 cases, 27%) a median of 1.8 months after diagnosis. After 5.1 months, 77% of participants had antibody decline (41% seroreverted; p<0.01), and 36% lost T-cell response (75% lost response to…
Previous page Next page